Gilead Sciences ((GILD)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences, in collaboration with Merck Sharp & Dohme LLC, is conducting a Phase 3 clinical study titled ‘An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)’. The study aims to compare the efficacy of pembrolizumab combined with sacituzumab govitecan against pembrolizumab alone in treating metastatic non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score of 50% or higher, focusing on progression-free survival and overall survival.
The interventions being tested include pembrolizumab, a biological treatment administered as an intravenous infusion, and sacituzumab govitecan, also a biological treatment given intravenously. The combination aims to enhance treatment efficacy for NSCLC patients.
This interventional study employs a randomized, parallel assignment model without masking, primarily targeting treatment outcomes. Participants are assigned to either the combination therapy group or the monotherapy group to evaluate differences in treatment effectiveness.
The study began on November 2, 2022, with primary completion expected by August 19, 2025. The last update was submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could impact clinical practices and market dynamics.
The update on this study could influence Gilead Sciences’ stock performance, as positive outcomes might boost investor confidence and market value. The study’s results could also affect the competitive landscape in the oncology sector, where numerous companies are vying for advancements in cancer treatment.
The study is currently recruiting participants, with further details available on the ClinicalTrials portal.